AbbVie Reports 9-Year VENCLEXTA Data in First-Line CLL
NORTH CHICAGO, Ill., June 12, 2026 AbbVie announced new long-term clinical results from the Phase 3 CLL14 trial at...
AbbVie
Advertisement
Servier Acquires Edgewise Muscular Dystrophy Business for $2.65B
SURESNES, France, June 1, 2026 Servier has announced a landmark agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in...
AbbVie Secures EU Approval for AQUIPTA as Acute Migraine Treatment
NORTH CHICAGO, Ill., June 2, 2026 AbbVie has announced that the European Commission (EC) has approved AQUIPTA® (atogepant) for...
AbbVie Secures EU Approval for Expanded VENCLYXTO Use in First-Line CLL
NORTH CHICAGO, Ill., May 29, 2026 AbbVie announced that the European Commission (EC) has approved an expanded label for...
AbbVie Wins FDA Approval for DECNUPAZ in Rare Blood Cancer
NORTH CHICAGO, Ill., May 27, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ™...
Advertisements
Allergan’s Boey Moves Closer to EU Approval for Glabellar Lines
North Chicago, Illinois, USA – May 21, 2026 Allergan Aesthetics, an AbbVie company and global leader in medical aesthetics,...
AbbVie Reports Strong Phase 3 Results for MAVIRET in Acute HCV
North Chicago, Illinois, USA – May 22, 2026 AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products...
AbbVie Expands Oncology Pipeline With New ASCO Data
North Chicago, Ill., USA – May 21, 2026 AbbVie announced new oncology research findings ahead of the 2026 American...
AbbVie Showcases IBD Data for Skyrizi and Rinvoq
NORTH CHICAGO, Ill., May 5, 2026 AbbVie Inc. has presented extensive new data across its gastroenterology portfolio at the...
Kestrel Therapeutics Doses First Patient in KRAS Trial
WATERTOWN, MASSACHUSETTS, April 28, 2026 Kestrel Therapeutics Inc. has announced a major clinical milestone with the first patient dosed...
Advertisement
